Effects of Exenatide on Glycemic Control and Weight in Continuous Subcutaneous Insulin Infusion (CSII) Type 2 Treated Patients With Type 2 Diabetes

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 110 participants.

Also called NCT01140893

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 110 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01140893
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
Not reported
Countries
France (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01140893. Randomized; quadruple masking; primary purpose treatment. Start 2010-11 (registry gives no type); primary completion 2017-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of Exenatide on Glycemic Control and Weight in Continuous Subcutaneous Insulin Infusion (CSII) Type 2 Treated Patients With Type 2 Diabetes
Acronym
EXEPUMP
Intervention (Drug)
Exenatide
Intervention (Drug)
Placebo
Lead sponsor
University Hospital, Caen (class: other)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01140893
Content hash
497b3b203f946bfc1879ea690447ef2a0201a408e4d65e62f0f996802c11ebd5